Suzhou Xianjue Biotechnology

Suzhou Xianjue Biotechnology is a Chinese biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic and endocrine diseases. The company primarily targets the incretin pathway, developing multi-receptor agonists such as GLP-1, GIP, and glucagon receptor modulators. Their research aims to address significant unmet needs in chronic conditions including type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). By leveraging advanced molecular design, Suzhou Xianjue Biotechnology seeks to create next-generation metabolic treatments with improved efficacy and safety profiles. The company is headquartered in the Suzhou Industrial Park, a major hub for biotechnology innovation in China.